Skip to main content

Pfizer Strengthens Manufacturing Capabilities in Asia

Pfizer Inc. announces a $100 million investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. This expansion, which brings the total investment in the plant to $372 million, makes it one of the largest nutritional plants worldwide.

"The expansion of our Singapore Nutrition Plant is one example of Pfizer's commitment to securing a healthy and sustainable future for our children," says Jeffrey B. Kindler, chairman and chief executive officer of Pfizer. "Our most valuable resources are our children and our environment, and Pfizer seeks to protect both by ensuring that our products for infants and children are manufactured to the most rigorous of safety and quality standards, with minimal environmental impact."

The expansion of the plant to 91,963 square meters (the equivalent of 17 football fields) has boosted the plant's production capacity by 50 percent and increased the plant's ability to supply nutrition products to Singapore and key markets such as China, Indonesia, Malaysia, Pakistan, Sri Lanka, Thailand, Taiwan, Hong Kong and Vietnam.

As part of the plant expansion, Pfizer has added over 100 new positions in the past year, bringing its staff strength to 587 people in total. The Pfizer Singapore Nutritional Plant achieves sustainability through the use of advanced technology aimed at maximizing energy efficiency and reducing waste. Over 50 percent of water used by the plant for maintenance purposes is recycled.
X
This ad will auto-close in 10 seconds